ReviewBest practice & research. Clinical rheumatology2020
The relationships between cancer and autoimmune rheumatic diseases.
Review in Best practice & research. Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Autoimmune disease patients with comorbid cancer exhibit prominent immunometabolic crosstalk.Science China. Life sciences · 2026Article
- Prescribing Biologic Immune-Modifying Therapies for Patients with a History of Cancer: A Cross-Specialty Review.Current oncology (Toronto, Ont.) · 2026Review
- Lifetime risk of malignancy in polymyalgia rheumatica: a population-based matched cohort study from southern Norway.Rheumatology (Oxford, England) · 2026Article
- Cervical cancer screening practices among patients with autoimmune and inflammatory rheumatic diseases: a descriptive cross-sectional observational study.BMC women's health · 2026Observational
- Cancer Association in Patients with Immune-Mediated Inflammatory Diseases: A Five-Year Nationwide Italian Cohort Study.Cancers · 2026Article
- An epidemiological study estimating the burden of cancer risk in patients with Raynaud's phenomenon.Clinical rheumatology · 2026Article
- Clinical Utility of 18F-FDG PET/CT in Rheumatology: Diagnostic and Therapeutic Insights from a Ten-Year Real-World Cohort.Journal of clinical medicine · 2026Article
- Advances in antibiofilm strategies for medical implant-associated infections: emerging technologies and translational challenges.Frontiers in microbiology · 2026Review
- Chimeric Antigen Receptor T-Cell Therapy and Autoimmune Diseases in the Nervous System.Immunity, inflammation and disease · 2025Review
- Cancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians.Journal of clinical medicine · 2025Review
- [Update on the treatment of rheumatic immune-related adverse events under immune checkpoint inhibition].Zeitschrift fur Rheumatologie · 2025Review
- Inflammatory Pathways to Carcinogenesis: Deciphering the Rheumatoid Arthritis-Lung Cancer Connection.Cancers · 2025Review
- Survival after surgery for lung cancer among patients with autoimmune diseases.Surgery today · 2025Article
- Insights into autoimmunity and cancer.Nature immunology · 2025Article
- Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue.Rheumatology and therapy · 2025Review
- Case report of concurrent ulcerative colitis and bilateral breast cancer: a literature review of the bidirectional association between autoimmune diseases and breast cancer.Frontiers in oncology · 2025Article
- Leveraging immune checkpoint inhibitors in lung cancer patients with pre-existing autoimmune disease: clinical insights, optimal timing, and predictive biomarkers for optimal treatment outcomes.Frontiers in immunology · 2025Review
- Biofilm-mediated immune dysregulation in chronic pulmonary diseases: mechanisms and clinical implications.Frontiers in microbiology · 2025Review
- Complement or insult: the emerging link between complement cascade deficiencies and pathology of myeloid malignancies.Journal of leukocyte biology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Links between autoimmune rheumatic diseases and cancer continue to be elucidated. In this review, we explore this complex, bidirectional relationship. First, the increased risk of cancer across the breadth of the autoimmune rheumatic diseases is described. The magnitude of risk and types of tumors seen can differ by the type of autoimmune disease, timing of disease course, and even clinical and laboratory features within a particular autoimmune disease, suggesting that targeted cancer screening strategies can be considered. Multiple mechanisms linking autoimmune rheumatic diseases and cancer are discussed, including the development of autoimmunity in the context of naturally occurring anti-tumor immune responses and malignancy arising in the context of inflammation and damage from autoimmunity. Immunosuppression for rheumatic disease can increase risk for certain types of cancers. Finally, immune checkpoint inhibitors, a type of cancer immunotherapy, which cause a variety of inflammatory syndromes of importance to rheumatologists, are reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.